share_log

Neurocrine Biosciences, Inc. Selects PANTHERxRare Specialty Pharmacy for Distribution of Crenessity (Crinecerfont)

Neurocrine Biosciences, Inc. Selects PANTHERxRare Specialty Pharmacy for Distribution of Crenessity (Crinecerfont)

神经分泌生物科学公司选择PANTHERxRare专业药房分销Crenessity(Crinecerfont)
PR Newswire ·  12/24 03:54

PITTSBURGH, Dec. 23, 2024 /PRNewswire/ -- PANTHERx Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Neurocrine Biosciences, Inc. for the distribution of CRENESSITY (crinecerfont), an oral selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist indicated to improve androgen control and enable a reduced glucocorticoid dose in patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH). CRENESSITY is the first non-steroidal treatment approved for classic CAH and a first-in-class therapy that provides a novel approach to treatment for this rare disorder.

匹兹堡,2024年12月23日 /PRNewswire/ — 美国罕见病产品患者准入和支持服务领域的领导者PantherX Rare欣然宣布,它被Neurocrine Biosciences, Inc.选中分销CRENESSITY(crinecerfont),这是一种口服选择性促肾上腺素释放因子(CRF1)受体拮抗剂,旨在改善雄激素控制和可以减少 4 岁及以上典型先天性肾上腺增生 (CAH) 患者的糖皮质激素剂量。CRENESSITY是第一种获准用于经典CAH的非甾体疗法,也是同类首创的疗法,为这种罕见疾病的治疗提供了一种新方法。

CAH is a rare, autosomal recessive genetic disorder that results from deficiency of one of the enzymes needed for adrenal hormone production. The most common cause of CAH is 21-hydroxylase (21-OHD) deficiency, which accounts for approximately 95% of cases.2 21-OHD deficiency prevents the body from producing cortisol, which is essential to respond to stress and illness. In about 75% of cases, aldosterone production is also affected, which impairs the body's ability to regulate salt and water levels, and thereby blood pressure.2,3 In response to low levels of cortisol and aldosterone, the hypothalamus-pituitary-adrenal (HPA) axis is activated, leading to overproduction of androgens.2 Excess androgen production can cause a variety of symptoms, including anxiety, acne, hirsutism, atypical genital development in affected females, fertility issues, early-onset puberty, and rapid growth followed by premature completion resulting in short stature.3 These symptoms can significantly impact both the physical and mental health of those affected with CAH.

CAH 是一种罕见的常染色体隐性遗传疾病,由缺乏产生肾上腺激素所需的一种酶引起。CAH 的最常见原因是 21-羟化酶(21-OHD)缺乏,约占病例的 95%。2 21-OHD 缺乏会阻止人体产生皮质醇,而皮质醇对应对压力和疾病至关重要。在大约 75% 的病例中,醛固酮的产生也会受到影响,这会损害人体调节盐和水水平的能力,从而降低血压。2,3 针对皮质醇和醛固酮的低水平,下丘脑-垂体-肾上腺(HPA)轴被激活,导致雄激素过度产生。2 雄激素分泌过多会导致各种症状,包括焦虑、痤疮、毛孔自闭症、受影响女性的非典型生殖器发育、生育问题、早发的青春期以及随之而来的快速成长导致的过早完成身材矮小3 这些症状会严重影响 CAH 患者的身心健康。

"We are proud to partner with Neurocrine Biosciences for the distribution of CRENESSITY. This collaboration underscores PANTHERx's dedication to providing personalized care and seamless access to transformative therapies for patients with rare and complex conditions," said Rob Snyder, Executive Chair, PANTHERx Rare Pharmacy.

“我们很荣幸能与Neurocrine Biosciences合作发行CRENESSITY。这种合作凸显了PantherX致力于为罕见和复杂疾病的患者提供个性化护理和无缝获得变革性疗法的决心。” PantherX稀有药房执行主席罗布·斯奈德说。

About PANTHERx Rare
PANTHERx Rare is a dual-accredited specialty pharmacy focused on rare and orphan disease, distributing several orphan products and providing access and support services to those needing them most. PANTHERx transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to people living with rare and devastating conditions. While each rare condition affects few people, together all rare diseases impact an estimated 25 to 30 million Americans.3 Currently over 7,000 rare diseases have been identified and more than 90% of rare diseases are still without an FDA-approved treatment. 3 Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community.

关于 PantherX Rare
PantherX Rare是一家双重认证的专业药房,专注于罕见病和孤儿病,分发多种孤儿产品,并为最需要这些产品的人提供准入和支持服务。PantherX 通过为患有罕见和毁灭性疾病的人们提供医学突破、卓越的临床表现和可获得的解决方案,从而改变生活。尽管每种罕见病影响的人数很少,但所有罕见疾病加起来影响估计有25至3000万美国人。3目前已发现超过7,000种罕见疾病,90%以上的罕见疾病仍未获得美国食品药品管理局批准的治疗方法。3 联邦政策的变化和科学的进步导致美国食品药品管理局孤儿药批准量激增,为罕见病界带来了巨大的希望。

PANTHERx is a dual-accredited specialty pharmacy, holding distinctions in rare disease including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and Utilization Review Accreditation Commission (URAC) Rare Disease Center of Excellence. As a pharmacy focused on patient satisfaction, PANTHERx is now a six-time winner of the prestigious MMIT Patient Choice Award, including the 2023 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania and is licensed in all 50 states and US territories.

PantherX是一家获得双重认证的专业药房,在罕见病领域拥有荣誉,包括医疗保健认证委员会(ACHC)孤儿药区别和利用审查认证委员会(URAC)罕见病卓越中心。作为一家注重患者满意度的药房,PantherX现已六次获得久负盛名的麻省理工学院患者选择奖,包括2023年的荣誉。PantherX 总部位于宾夕法尼亚州匹兹堡,在美国所有 50 个州和地区均获得许可。

1. CRENESSITY (crinecerfont) [package insert]. Neurocrine Biosciences, Inc. 2024.
2. Congenital Adrenal Hyperplasia (CAH). Neurocrine Biosciences, Inc. Accessed October 21, 2024.
3. Congenital Adrenal Hyperplasia. NORD (National Organization for Rare Disorders). Published June 8, 2023. Accessed October 21, 2024.

1。CRENESSITY (crinecerfont) [包装说明书]。Neurocrine Biosciences, Inc. 2024.
2。先天性肾上腺皮质增生(CAH)。Neurocrine Biosciences, Inc. 于 2024 年 10 月 21 日访问。
3.先天性肾上腺皮质增生。NORD(全国罕见疾病组织)。发布于 2023 年 6 月 8 日。已于 2024 年 10 月 21 日访问。

For more information, please contact [email protected]

欲了解更多信息,请联系 [email protected]

SOURCE PANTHERx Rare Pharmacy

来源 PantherX 稀有药房

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想在 PRNEWSWIRE.COM 上刊登贵公司的新闻吗?

440k+
440k+

Newsrooms &
新闻编辑室和

Influencers
有影响力的人
9k+
9k+

Digital Media
数字媒体

Outlets
网点
270k+
270k+

Journalists
记者

Opted In
选择加入
GET STARTED
开始吧
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发